This observational study compares the efficacy and safety of tigecycline, an alternative antibiotic with broad-spectrum activity, versus the standard colistimethate sodium-based regimen in managing these infections in pediatric patients. Inclusion Criteria: Pediatric patients aged 1 month to 18 years. Presence of CNS infection symptoms such as fever, altered mental status, and positive cerebrospinal fluid (CSF) findings. EVD placement for managing CNS infections. Exclusion Criteria: Known allergy to tigecycline or colistimethate sodium. Patients with concurrent severe comorbid conditions that may confound study results. Neonates (less than 1 month old), pregnant, or breastfeeding patients. Outcome Measures: Primary Outcomes: Clinical cure (resolution of infection symptoms) and microbiological cure (sterilization of CSF cultures). Secondary Outcomes: Mortality rates and adverse drug events, such as nephrotoxicity, hepatotoxicity, chemical meningitis, or seizures.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Microbiological eradication
Timeframe: follow up of the patients from time of enrollment to end of treatment is for 14-21 days
Clinical Cure rate
Timeframe: follow up of the patients from time of enrollment to end of treatment is for 14-21 days